Dedicated to cardiovascular health, Heart Failure POC & LOC Devices companies focus on developing Point-of-Care (POC) and Lab-on-Chip (LOC) devices. Their innovative solutions enable rapid and accurate diagnostics for heart failure, supporting timely interventions and improving patient outcomes in cardiovascular care.
Abbott Laboratories Launched the i-STAT BNP Test in December 2023, offering a rapid and portable POC test for B-type natriuretic peptide (BNP), a key marker for heart failure.
Roche Diagnostics Introduced the Elecsys® proBNP 2nd Generation assay in July 2023, providing increased sensitivity and specificity for BNP testing on their laboratory analyzers.
Lumio Diagnostics Received FDA clearance for their LUMIO™ Platform in October 2023, which includes a portable system for rapid, multi-analyte testing, including biomarkers for heart failure.
Singal™ Biometrics Developing a LOC device capable of simultaneously measuring multiple heart failure biomarkers on a single chip, offering rapid and comprehensive diagnosis.
Cardiome Dx Collaborating with other companies to develop and integrate AI-powered algorithms into their heart failure POC devices, enhancing diagnostic accuracy and providing real time insights.
Abbott (US)
F. Hoffmann-La Roche Ltd. (Switzerland)
Danaher (US)
Abaxis, Inc. (US)
Quidel Corporation (US)
Siemens Healthineers (Germany)
JantPharmacal Corporation (US)
Trinity Biotech (Ireland)
bioMĂ©rieux S.A (France)
Instrumentation Laboratory Company (US)
Heart Failure POC and LOC Devices Market Highlights:
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)